Effects on overall lipid profile
Treatment with pegozafermin resulted in improvements in non-HDL-C and apolipoprotein B (ApoB), with least squares (LS) mean percent changes from baseline for pooled pegozafermin of −18.3% versus −0.6% for placebo (−17.9% placebo-corrected, 95% CI: −30.7%, −5.1%; 